Ocular Therapeutix’s (OCUL) Outperform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada restated their outperform rating on shares of Ocular Therapeutix (NASDAQ:OCUL) in a research note released on Wednesday,Benzinga reports. They currently have a $30.00 price target on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on the stock. Chardan Capital reaffirmed a “buy” rating and set a $21.00 target price on shares of Ocular Therapeutix in a research note on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Tuesday, April 21st. Needham & Company LLC lowered their target price on shares of Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Finally, Wall Street Zen cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $23.78.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL opened at $9.65 on Wednesday. The firm has a market cap of $2.11 billion, a PE ratio of -6.61 and a beta of 0.93. The firm has a fifty day moving average of $9.08 and a 200 day moving average of $10.51. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.32 and a current ratio of 14.81. Ocular Therapeutix has a one year low of $6.23 and a one year high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. Ocular Therapeutix had a negative net margin of 558.24% and a negative return on equity of 64.28%. The company had revenue of $13.25 million for the quarter, compared to analysts’ expectations of $16.13 million. During the same quarter in the previous year, the company posted ($0.29) EPS. The firm’s quarterly revenue was down 22.4% on a year-over-year basis. As a group, research analysts predict that Ocular Therapeutix will post -1.52 EPS for the current fiscal year.

Insider Activity

In other news, COO Donald Notman sold 11,446 shares of the business’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $103,471.84. Following the transaction, the chief operating officer owned 366,356 shares of the company’s stock, valued at approximately $3,311,858.24. The trade was a 3.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard L. Md Lindstrom purchased 60,229 shares of the stock in a transaction dated Friday, February 20th. The shares were purchased at an average cost of $7.66 per share, for a total transaction of $461,354.14. Following the transaction, the director owned 246,933 shares in the company, valued at approximately $1,891,506.78. The trade was a 32.26% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have sold 185,731 shares of company stock worth $1,653,407. Insiders own 2.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Steward Partners Investment Advisory LLC raised its holdings in Ocular Therapeutix by 124.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,242 shares during the period. Rockefeller Capital Management L.P. purchased a new stake in Ocular Therapeutix in the 4th quarter valued at about $31,000. Hilton Head Capital Partners LLC purchased a new stake in Ocular Therapeutix in the 4th quarter valued at about $42,000. Atlas Capital Advisors Inc. purchased a new stake in Ocular Therapeutix in the 4th quarter valued at about $61,000. Finally, State of Wyoming purchased a new stake in Ocular Therapeutix in the 4th quarter valued at about $78,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix News Summary

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Needham & Company reiterated a Buy rating and set an $18 price target, implying meaningful upside from recent levels.
• Positive Sentiment: HC Wainwright also maintained a Buy rating and $21 price target, even while trimming some earnings estimates, which suggests analysts still see substantial long-term value.
• Positive Sentiment: The company announced inducement stock grants for 12 newly hired non-executive employees, a routine hiring-related move that may support execution as Ocular expands its team. Article Title
• Neutral Sentiment: HC Wainwright lowered near-term and full-year EPS estimates for 2026-2027, reflecting softer profitability expectations even as the firm kept a bullish rating.
• Neutral Sentiment: New commentary on SOL-1 / SOL-X and AXPAXLI highlights ongoing clinical-trial progress, but also points to adoption and valuation questions that are keeping some investors cautious.
• Negative Sentiment: Some recent analysis has focused on valuation concerns and volatile returns, which can pressure sentiment despite the company’s clinical pipeline progress.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.